JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Portfolio Pulse from Vandana Singh
JP Morgan has shown interest in the specialty pharma sector, highlighting Teva and Organon. The sector shows stability with modest growth, and valuations have recovered. JP Morgan maintains a Neutral rating on Teva and Viatris, an Overweight rating on Perrigo and Amphastar, and adjusts ratings for Amneal and Organon.
September 06, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Amphastar, anticipating promising catalysts into 2024/2025.
The Overweight rating and anticipation of future catalysts suggest a positive short-term impact on Amphastar's stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
JP Morgan upgrades Amneal to Neutral from Underweight, noting potential for improved financial forecasts.
The upgrade to Neutral suggests a potential positive impact on Amneal's stock price due to improved financial forecasts.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 65
POSITIVE IMPACT
JP Morgan holds an Overweight rating on Perrigo, expecting EPS rebound and potential valuation increase.
The Overweight rating and expected EPS rebound suggest a positive short-term impact on Perrigo's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 75
NEUTRAL IMPACT
JP Morgan maintains a Neutral rating on Teva, noting a bullish sentiment but cautioning about its U.S. generic business.
JP Morgan's Neutral rating suggests that the market has already priced in Teva's prospects, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
JP Morgan gives Viatris a Neutral rating due to stable fundamentals and low valuation amidst business uncertainties.
The Neutral rating reflects stable fundamentals but also highlights uncertainties, leading to a neutral short-term impact.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
JP Morgan downgrades Organon to Underweight from Neutral, despite a 60% YTD price increase.
The downgrade to Underweight suggests a negative short-term impact on Organon's stock price, despite recent gains.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75